Who founded Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals was founded by John Maraganore, Phillip Sharp, David Bartel, Thomas Tuschl, Paul Schimmel, Phillip Zamore in 2002.

Who are Alnylam Pharmaceuticals's investors?

Alnylam Pharmaceuticals's investors include ARCH Venture Partners, Atlas Venture, Blackstone Life Sciences, Cardinal Partners, Invivo Capital Partners.

Where is Alnylam Pharmaceuticals headquartered?

Alnylam Pharmaceuticals is headquartered in Cambridge, US.

Alnylam Pharmaceuticals

NASDAQ: ALNYUnicorn · $31.2B

Cambridge, US · Founded 2002 · 3,026 employees on LinkedIn · 5 known investors

Find your way into Alnylam Pharmaceuticals

1,309 people in our graph share verified history with the Alnylam Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

Carol Suhunlockedknows John Maraganore · together at Orbital Therapeutics (overlapped)

knows the team · via Biotechnology Innovation Organization

×2knows the team · via Omega Funds

×2knows the team · via Alnylam

×6knows the team · via ARCH Venture Partners

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

Also known as ALNY · Alnylam Pharmaceuticals · Alnylam Pharmaceuticals, Inc.

Biotech Digital Health Medical Devices

Founders & leadership

John Maraganore Co-founder · Chief Executive Officer2002–2021John Maraganore holds a B.A., M.S., and Ph.D. from the University of Chicago's Division of Biological Sciences, and earlier held research roles at Upjohn, Zymogenetics, Biogen (where he invented the thrombin inhibitor bivalirudin), and Millennium Pharmaceuticals. He was the founding CEO of Alnylam Pharmaceuticals from 2002 to 2021, where he led its development of RNA interference therapeutics, and now runs JMM Innovation LLC while serving on numerous biotech boards and as an investment advisor.

Phillip SharpFounder

David BartelFounder

Thomas TuschlFounder

Paul SchimmelFounder

Phillip ZamoreFounder

Dr. Yvonne GreenstreetChief Executive OfficerFounder at Alnylam

Jeffrey V. PoultonExecutive Vice President and Chief Financial Officer

Bryan A. Supran EVP & Chief Legal OfficerBryan Supran is Executive Vice President and Chief Legal Officer at Alnylam, a biopharmaceutical company supporting investigator-initiated studies in rare genetic diseases. He spent over two decades at Pfizer as Senior Vice President and Deputy General Counsel, where he oversaw corporate, transactional, intellectual property, regulatory, and litigation matters, and previously served as chief securities and corporate counsel at Wyeth before its merger with Pfizer; he holds a J.D. from New York University School of Law and a B.A. in Politics and East Asian Studies from Princeton University.

Pushkal Garg Chief Research & Development OfficerPushkal Garg is Executive Vice President and Chief Research and Development Officer at Alnylam, a biopharmaceutical company developing RNAi-based therapeutics for rare and common diseases.

Tolga TangulerExecutive Vice President, Chief Commercial OfficerChief Commercial Officer at Alnylam

Kevin J. Fitzgerald Chief Scientific OfficerKevin J. Fitzgerald is Executive Vice President and Chief Scientific Officer at Alnylam, a biopharmaceutical company developing RNAi-based therapeutics for rare diseases including transthyretin-mediated amyloidosis and primary hyperoxaluria. He brings over 25 years of drug development experience across multiple modalities, including work on approved and clinical-stage therapies, with expertise in orphan disease development, oncology, and metabolic disease.